JP2022525927A5 - - Google Patents

Info

Publication number
JP2022525927A5
JP2022525927A5 JP2021556491A JP2021556491A JP2022525927A5 JP 2022525927 A5 JP2022525927 A5 JP 2022525927A5 JP 2021556491 A JP2021556491 A JP 2021556491A JP 2021556491 A JP2021556491 A JP 2021556491A JP 2022525927 A5 JP2022525927 A5 JP 2022525927A5
Authority
JP
Japan
Prior art keywords
cell
cells
polypeptide
domain
cell according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021556491A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525927A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2020/050327 external-priority patent/WO2020188570A1/en
Publication of JP2022525927A publication Critical patent/JP2022525927A/ja
Publication of JP2022525927A5 publication Critical patent/JP2022525927A5/ja
Pending legal-status Critical Current

Links

JP2021556491A 2019-03-19 2020-03-19 Ｆｃガンマ受容体を発現するｔ細胞およびその使用方法 Pending JP2022525927A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962820357P 2019-03-19 2019-03-19
US62/820,357 2019-03-19
PCT/IL2020/050327 WO2020188570A1 (en) 2019-03-19 2020-03-19 T cell expressing an fc gamma receptor and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2022525927A JP2022525927A (ja) 2022-05-20
JP2022525927A5 true JP2022525927A5 (enExample) 2023-03-27

Family

ID=72519182

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556491A Pending JP2022525927A (ja) 2019-03-19 2020-03-19 Ｆｃガンマ受容体を発現するｔ細胞およびその使用方法

Country Status (8)

Country Link
US (2) US20210401893A1 (enExample)
EP (1) EP3941492A4 (enExample)
JP (1) JP2022525927A (enExample)
CN (1) CN113853205A (enExample)
AU (1) AU2020243623A1 (enExample)
CA (1) CA3133037A1 (enExample)
IL (1) IL286477A (enExample)
WO (1) WO2020188570A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021260696A1 (en) 2020-06-22 2021-12-30 Ramot At Tel-Aviv University Ltd. Multi subunit protein modules, cells expressing same and uses thereof
WO2024154122A1 (en) 2023-01-18 2024-07-25 Gilboa Therapeutics LTD Immune cells expressing a complement receptor and uses thereof
WO2024236557A1 (en) 2023-05-12 2024-11-21 Gilboa Therapeutics LTD Compositions comprising an fc domain for the treatment of medical conditions
CN117660500B (zh) * 2023-09-28 2025-01-28 上海恩凯细胞技术有限公司 核酸构建体、载体、转基因免疫细胞及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641863A (en) * 1993-09-30 1997-06-24 University Of Pennsylvania Chimeric IgG Fc receptors
ES2678094T3 (es) * 2004-07-10 2018-08-08 Fox Chase Cancer Center Líneas de células asesinas naturales genéticamente modificadas
US10144770B2 (en) * 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
WO2015179833A1 (en) * 2014-05-23 2015-11-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treating antibody resistance
WO2016040441A1 (en) * 2014-09-09 2016-03-17 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy
US10577417B2 (en) * 2014-09-17 2020-03-03 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
KR20170127015A (ko) * 2015-03-13 2017-11-20 유니버시티 오브 매릴랜드, 발티모어 만능항체 매개 바이오센서

Similar Documents

Publication Publication Date Title
Sommermeyer et al. Fully human CD19-specific chimeric antigen receptors for T-cell therapy
Hombach et al. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA
US12076378B2 (en) Use of car and bite technology coupled with an SCFV from an antibody against human thymidine kinase 1 to specifically target tumors
D’Aloia et al. CAR-T cells: the long and winding road to solid tumors
Hombach et al. T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells
CN113698490B (zh) 靶向cea的缺氧诱导启动的car结构及免疫细胞和应用
KR102091297B1 (ko) 항원-형질감염된 t 세포와 함께 사용되는 이중특이적 항체 분자 및 의약에서의 이들의 용도
Hombach et al. T cell activation by recombinant FcεRI γ-chain immune receptors: an extracellular spacer domain impairs antigen-dependent T cell activation but not antigen recognition
JP2025023921A (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
US20200093861A1 (en) Antigen binding receptor formats
JP2021512635A5 (enExample)
US20190216908A1 (en) Adoptive T-Cell Therapy
JP2024023228A5 (enExample)
EP4400516A1 (en) Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
JP2021529559A5 (enExample)
CN111246861A (zh) 扩增表达重组受体的细胞的试剂
Arndt et al. Simultaneous targeting of prostate stem cell antigen and prostate‐specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell‐retargeting system
JP2024540359A (ja) Ｔｅａｍを分泌する抗メソテリンｃａｒｔ細胞とその使用方法
CN115698081A (zh) 靶向bcma的嵌合抗原受体及其用途
EP1413316A1 (en) Bifunctional conjugates or fusion proteins
JP2025513626A (ja) Ｃｉｉｔａ遺伝子がノックアウトされた操作された免疫細胞及びその用途
Heuser et al. An anti-MUC1-antibody–interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells
AU2019221544B2 (en) Methods and compositions for targeting Treg cells
WO2025109493A1 (en) Chimeric Receptors with Binding Capacity for Antibodies
JP2025506515A5 (enExample)